Merck & Co., Inc. MRK shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance.
The Merck Analysts
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107 price target.
SVB Leerink analyst Daina Graybosch maintained an Outperform rating and lowered the price target from $98 to $95.
Q1 Underlines Merck's Fundamental Strength, Cantor Says
Some parts of Merck's business benefited from stocking/panic buying, while the pandemic uncertainty led to a reduction in guidance, Cantor analyst Chen said in a Tuesday note.
The strong quarterly results underscore the long-term fundamental strength of the company's business, the analyst said.
Merck's cancer immunotherapy Keytruda notched sales of $3.284 billion, ahead of the $3.24-billion consensus estimate following a shortfall in the fourth quarter of 2019, she said.
The reduced full-year guidance factors in reduced access to hospitals and other health care sites; the virus outbreak peaking in the second quarter in the U.S. and Europe; social distancing remaining in force through the third quarter; and a full return to normal operations in the fourth quarter, Chen said.
"Sales growth across oncology, vaccines, animal health, and select hospital/specialty care products as well as margin expansion opportunities, remain underappreciated, in our view."
Cantor expects multiple expansion to drive Merck shares higher.
See Also: Gilead's Remdesivir Reaches Goal In NIAID-Sponsored Coronavirus Trial
SVB Leerink Projects Strong Keytruda Sales In 2020
The operational changes Merck is bringing about to mitigate the COVID-19 risk to clinical trials could translate to a small mid-term competitive advantage, SVB Leerink analyst Graybosch said in a Tuesday note.
The analyst expects Keytruda sales to remain strong in 2020, with the six-week dosing approved Tuesday adding to its advantage as the "tried-and-true" option for patients treated during the pandemic.
Merck is using the full strength of its vaccine organization for the COVID-19 task, she said.
The guidance reduction primarily reflects a largely physician-administered portfolio, strong dollar and exposure to animal health, according to SVB Leerink.
MRK Price Action
After ending Tuesday's session down 3.33% at $81.18, Merck shares were trading down another 1.85% at $79.68 at the time of publication Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.